Article Text

This article has been retracted. Please see:

other Versions

PDF
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications. A study from the Lunenburg Lymphoma Biomarker Consortium (LLBC)
  1. Daphne de Jong (d.d.jong{at}nki.nl)
  1. The Netherlands Cancer Institute, Netherlands
    1. Wanling Xie
    1. Dana-Farber Institute, United States
      1. Andreas Rosenwald
      1. University of Wurzburg, Germany
        1. Mukesh Chhanabhai
        1. British Columbia Cancer Center, Canada
          1. Philippe Gaulard
          1. Hopital Henri Mondor, France
            1. Wolfram Klapper
            1. University of Schleswig-Holstein, Germany
              1. Abigail Lee
              1. St. Bartholomew's Hospital, United Kingdom
                1. Birgitta Sander
                1. Karolinska Institutet, Sweden
                  1. Christoph Thorns
                  1. University of Schleswig-Holstein/Lubeck, Germany
                    1. Elias Campo
                    1. University of Barcelona, Spain
                      1. Thierry Molina
                      1. Universite Paris-Descartes, France
                        1. Anton Hagenbeek
                        1. University Medical Center Amsterdam, Netherlands
                          1. Sandra Horning
                          1. Stanford University Medical Center, United States
                            1. Andrew Lister
                            1. St. Bartholomew's Hospital, United Kingdom
                              1. John Raemaekers
                              1. University Medical Center Nijmegen, Netherlands
                                1. Gilles Salles
                                1. Hospices Civils de Lyon, France
                                  1. Randy Gascoyne
                                  1. British Columbia Cancer Center, Canada
                                    1. Edie Weller
                                    1. Dana-Farber Cancer Institute, United States

                                      Abstract

                                      The results of class prediction and the determination of prognostic markers in DLBCL have been variably reported. Apart from biological variations, this may be caused by differences in laboratory techniques, scoring definitions and inter- and intra-observer variation. In this study, an international collaboration of clinical lymphoma research groups has concentrated on validation and standardization of immunohistochemistry of the currently potentially interesting prognostic markers in DLBCL.

                                      Sections of a tissue microarray with 36 cases of DLBCL were stained in 8 laboratories with antibodies to CD20, CD5, bcl-2, bcl-6, CD10, HLA-DR, MUM1 and Ki-67 according to local methods. The study was performed in two rounds firstly focused on the evaluation of laboratory staining variation and secondly on the scoring variation.

                                      Different techniques resulted in highly variable results and poor reproducibility for almost all markers. Reproducibility of the nuclear markers was highly sensitive to technical variations, including immunological enhancement techniques (agreements 34%). With elimination of variation due to staining and uniformly agreed upon scoring criteria, significant improvement was seen, however less so for bcl-6 and Ki-67 (agreement 53-58%). Absence of internal controls that preclude scoring, significantly influenced the results for CD10 and bcl-6.

                                      This study shows that semi-quantitative immunohistochemistry for subclassification of DLBCL is feasible, but with varying rates of concordance for different markers and only using optimized techniques and strict scoring criteria. These findings may explain the wide variation in prognostic impact reported in the literature. Harmonization of techniques and centralized consensus review appears mandatory when using immunohistochemical biomarkers for treatment stratification.

                                      Statistics from Altmetric.com

                                      Request permissions

                                      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                                      Linked Articles

                                      • Postscript
                                        BMJ Publishing Group Ltd and Association of Clinical Pathologists